Skip to content

EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales ("RAPID")

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-520067-13-00
Enrollment
80
Registered
2026-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloodstream Infection, Ventilator Associated Pneumonia and Hospital-Acquired Pneumonia

Brief summary

Composite endpoint of all-cause mortality and/or no improvement in Sequential Organ Failure Assessment (SOFA) score at Day 14 post index culture

Detailed description

Clinical response at Day 7 and Day 14 post index culture, as defined by a set of clinical criteria signifying cardiopulmonary stability for 48 hours, All-cause mortality at Day 14, Day 28, and Day 60 post index culture, Days alive and out of hospital in the 60 days from date of index culture, Length of stay in ICU in the 60 days from date of index culture, Length of stay in hospital in the 60 days from date of index culture, Type of accommodation on discharge from hospital, Duration of mechanical ventilation in the 60 days from date of index culture, Persistence of bacteremia at Day 4 from date of index blood culture, Persistence of microbiologic growth at Day 7 from date of index respiratory culture, of at least one organism growing from index respiratory culture, Development of resistance to meropenem or ceftazidime-avibactam in any bacteria grown from clinically-indicated cultures collected in the 28 days from date of index culture, Development of acute kidney injury (modified KDIGO definitions) in the 28 days from date of index culture<, Development of Clostridioides difficile diarrhea in the 28 days from date of index culture collection, Time from index culture sample received by the laboratory to antibiotic therapy active in vitro (in hours)<, Percentage of patients undergoing modification of antibiotic therapy in the 7 days after microbiology diagnostics for the index culture, Number of days on antibiotics in the 28 days from date of index culture collection (total, and by antibiotic type)<, Time from index culture sample received by the laboratory to detection of carbapenem resistance (in hours, Time from index culture sample received by the laboratory to detection of resistance to ceftriaxone/cefotaxime (in hours)<, Time from index culture sample received by the laboratory to detection of Acinetobacter baumannii calcoaceitcus complex or Stenotrophomonas maltophilia (in hours, Functional outcome at Day 28 and Day 60 from collection of index culture, Composite outcome measure defined by Desirability of Outcome Ranking (DOOR) at Day 28 from index culture sample, Cost-effectiveness of the Intervention, compared to Control, from the health system perspective, Up to 60 days from date of index culture

Interventions

Sponsors

National University Of Singapore
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Composite endpoint of all-cause mortality and/or no improvement in Sequential Organ Failure Assessment (SOFA) score at Day 14 post index culture

Secondary

MeasureTime frame
Clinical response at Day 7 and Day 14 post index culture, as defined by a set of clinical criteria signifying cardiopulmonary stability for 48 hours, All-cause mortality at Day 14, Day 28, and Day 60 post index culture, Days alive and out of hospital in the 60 days from date of index culture, Length of stay in ICU in the 60 days from date of index culture, Length of stay in hospital in the 60 days from date of index culture, Type of accommodation on discharge from hospital, Duration of mechanical ventilation in the 60 days from date of index culture, Persistence of bacteremia at Day 4 from date of index blood culture, Persistence of microbiologic growth at Day 7 from date of index respiratory culture, of at least one organism growing from index respiratory culture, Development of resistance to meropenem or ceftazidime-avibactam in any bacteria grown from clinically-indicated cultures collected in the 28 days from date of index culture, Development of acute kidney injury (modified KDIGO

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 30, 2026